Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas-Reference-Cited by-同舟云学术

Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas

Published:2012-12-17 Issue:1 Volume:229 Page:111-120
ISSN:0022-3417
Container-title:The Journal of Pathology
language:en
Short-container-title:J. Pathol.

Author:

Anglesio Michael S¹,Kommoss Stefan¹,Tolcher Mary C²,Clarke Blaise³,Galletta Laura⁴,Porter Henry¹,Damaraju Sambasivarao⁵,Fereday Sian⁴,Winterhoff Boris J²,Kalloger Steve E⁶,Senz Janine¹,Yang Winnie⁷,Steed Helen⁸,Allo Ghassan³,Ferguson Sarah⁹,Shaw Patricia¹⁰,Teoman Attila¹¹,Garcia Joaquin J¹¹,Schoolmeester John K¹¹,Bakkum-Gamez Jamie¹¹,Tinker Anna V¹²,Bowtell David D,Huntsman David G,Gilks C Blake,McAlpine Jessica N¹³

Affiliation:

1. Department of Pathology and Laboratory Medicine; University of British Columbia; Vancouver; British Columbia; Canada

2. Department of Obstetrics and Gynecology; Mayo Clinic; Rochester; Minnesota; USA

3. Department of Laboratory Medicine and Pathobiology; University of Toronto; Toronto; Ontario; Canada

4. Australian Ovarian Cancer Study Group; Peter MacCallum Cancer Centre; Melbourne; Australia

5. Canadian Breast Cancer Foundation Tumor Bank, Alberta Health Services and Laboratory Medicine and Pathology; University of Alberta; Edmonton; Alberta; Canada

6. Genetic Pathology Evaluation Centre, VGH and UBC; Vancouver; British Columbia; Canada

7. Centre for Translational and Applied Genomic, BC Cancer Agency; Vancouver; British Columbia; Canada

8. Department of Obstetrics and Gynecology, and Division of Gynecologic Oncology; University of Alberta; Edmonton; Alberta; Canada

9. Department of Gynecologic Oncology; University of Toronto; Toronto; Ontario; Canada

10. Toronto General Hospital; University Health Network, University of Toronto; Toronto; Ontario; Canada

11. Department of Pathology; Mayo Clinic; Rochester; Minnesota; USA

12. Department of Medical Oncology; BC Cancer Agency; Vancouver; British Columbia; Canada

13. Department of Obstetrics and Gynecology; University of British Columbia and BC Cancer Agency; Vancouver; British Columbia; Canada

Publisher

Wiley

Subject

Pathology and Forensic Medicine

Reference55 articles.

1. Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data;Gilks;Int J Gynecol Pathol,2004

2. Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis;Seidman;Am J Surg Pathol,2003

3. Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7;Vang;Mod Pathol,2006

4. Distinction of primary and metastatic mucinous tumors involving the ovary: analysis of size and laterality data by primary site with reevaluation of an algorithm for tumor classification;Yemelyanova;Am J Surg Pathol,2008

5. Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory;Kurman;Am J Surg Pathol,2010

Cited by 165 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Heterogeneity and treatment landscape of ovarian carcinoma;Nature Reviews Clinical Oncology;2023-10-02

2. Durable remission in a patient with ERBB2-amplified recurrent mucinous ovarian carcinoma treated with Trastuzumab-Carboplatin-Paclitaxel;Gynecologic Oncology Reports;2023-08

3. ATAD2 is a driver and a therapeutic target in ovarian cancer that functions by upregulating CENPE;Cell Death & Disease;2023-07-21

4. HER2/ERBB2 Immunohistochemical Expression and Copy Number Status in Ovarian Mucinous Tumors;International Journal of Gynecological Pathology;2023-06-30

5. Rare Epithelial Ovarian Cancers: Low Grade Serous and Mucinous Carcinomas;Cold Spring Harbor Perspectives in Medicine;2023-06-05